Alios banks $60 million in HCV nucleotide analogue deal with Vertex
This article was originally published in Scrip
Executive Summary
Hot off its US approval of its hepatitis C virus (HCV) protease inhibitor Incivek (telaprevir), which is expected to change the way the disease is treated, Vertex Pharmaceuticals has signed an exclusive worldwide licensing deal gaining the rights to two HCV nucleotide analogues from Alios BioPharma in exchange for $60 million up front.